Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

CEO Justin Hanka provides update on Phase 2B clinical trials.

Hi The journey to bring a new mental health treatment to market is a rigorous one, but the potential of MindBio Therapeutics’ lead candidate, MB22001, makes it all worthwhile. We’re thrilled to share that MB22001 is showing exceptional promise in add...

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4